ROBERT NEBORSKY: Open Payments
NPI 1871610345 · DEL MAR, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$661 in 22 payments from 9 companies in 2025. Trend: 2023 $1,447 · 2024 $1,071 · 2025 $661
Food & beverage: $661
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $194 |
| Alkermes, Inc. | 1 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $109 |
| Lundbeck LLC | 3 | $68 |
| Janssen Pharmaceuticals, Inc | 3 | $62 |
| ABBVIE INC. | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
Products named: REXULTI, LYBALVI, TRINTELLIX, SPRAVATO, VRAYLAR, Auvelity, FANAPT, CAPLYTA.
Industry payments across CA — which companies pay providers there.
